<DOC>
	<DOCNO>NCT02111499</DOCNO>
	<brief_summary>Clinical investigation anti-psoriatic efficacy atrophy</brief_summary>
	<brief_title>Efficacy , Tolerability Safety LAS41004 Formulations Psoriasis Plaque Test</brief_title>
	<detailed_description>In trial three concentration bexarotene combination fix concentration betamethasone dipropionate , well monotherapy bexarotene , investigate regard efficacy , tolerability safety patient mild moderate plaque psoriasis compare vehicle active comparator . Since side effect application corticosteroid skin atrophy , additionally three non-lesional test area ( affected psoriasis ) volar forearm treat active reference product , one fix combination vehicle . Skin atrophy investigate visual assessment ultrasound test area</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Main 18 75 year age Men woman skin type I IV ( Fitzpatrick 1974 ) . Suffering mild moderate plaque psoriasis least 6 month duration amenable local therapy . With least one stable psoriatic plaque area sufficient product application meeting follow criterion : Located trunk and/or extremity ( plaque locate head , palm , sole foot , intertriginous genitoanal area suitable ) . Plaques clinical score parameter erythema induration ≥ 2 sign screen visit . At Day 1 parameter score ≥ 2 . Where one plaque use , plaque comparable , least `` 2 '' score erythema induration . • Body surface area ( BSA ) involvement &lt; 10 % . Prepared give write informed consent specific trial , assessment perform . • In case woman childbearing potential use reliable method contraception result low failure rate i.e . le 1 % per year ( e.g . contraceptive implant injectables , combine oral contraceptive , intrauterine device , sexual abstinence vasectomize partner ) . During study additional barrier method ( e.g . condom ) use . Nonchildbearing potential defined surgical sterilization ( hysterectomy , ovariectomy tubal ligation ) , postmenopausal status ( continuous amenorrhea least 2 year ) . In case men partner childbearing potential willingness use condom study conduct 1 month end treatment . Main • Patients need systemic treatment psoriasis . Severe form psoriasis form psoriasis chronic plaque psoriasis , Systemic treatment ( see table ) : Corticosteroids , antibiotic 4 week prior trial Day 1 conduct trial Retinoids Ciclosporin Methotrexate Fumaric acid ester 3 month prior trial Day 1 conduct trial Antiinflammatory substance , NSAIDs 2 week prior trial Day 1 conduct trial Biologics 6 month prior trial Day 1 conduct trial Topical treatment body region corticosteroids immunosuppressant 20 % body surface area treat . Diseases : Significant skin infection cause bacteria , virus fungi , include limited tuberculosis , syphilis varicella zoster infection Parasitic infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>psoriasis plaque test</keyword>
	<keyword>topical application</keyword>
	<keyword>atrophy measure</keyword>
</DOC>